Akoya Biosciences Reports First Quarter 2024 Financial Results

Clinical ResultFinancial StatementPhase 2
Akoya Biosciences Reports First Quarter 2024 Financial Results
MARLBOROUGH, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2024.
Business Highlights
Revenue was $18.4 million in the first quarter of 2024, compared to $21.4 million in the prior year period; a decrease of 14%. Reagents and services revenue continued to increase.
Akoya announced the establishment of a new Manufacturing Center of Excellence in Marlborough, Massachusetts to scale internal reagent manufacturing to meet the accelerating demand for reagents.
Akoya’s partner Acrivon Therapeutics presented initial positive Phase 2b clinical data for the ACR-368 therapeutic in patients positive for the ACR-368 OncoSignature Assay in ovarian and endometrial cancer, deployed on the PhenoImager HT platform.
Akoya and NeraCare, a leading developer of laboratory tests for the prognosis of melanoma patients, announced an exclusive partnership to enable personalized therapy selection for early-stage melanoma patients at high risk of relapse and death.
Akoya and Shanghai KR Pharmtech announced that the KR-HT5 instrument, based on the PhenoImager HT, has received premarket approval from China’s National Medical Products Administration (NMPA).
“While we made meaningful progress in advancing both our operational and clinical objectives, our first quarter results fell short of expectations due to three main factors. First, systemic pressure on capital expenditures persisted. Second, certain pharmaceutical partner lab services revenue were deferred to the second half of 2024 due to revised clinical trial milestones. Third, the completion and launch of our fully operational Manufacturing Center of Excellence temporarily impacted reagent fulfillment times, delaying instrument purchases,” said Brian McKelligon, CEO of Akoya Biosciences. “With the industry’s leading installed base, normalization of pharmaceutical partner revenue in the second half of 2024, and now resolved reagent availability issues, we believe that our foundational initiatives will lead us back to strong top-line growth and achievement of our profitability objectives.”
First Quarter 2024 Financial Results
Revenue was $18.4 million in the first quarter of 2024, compared to $21.4 million in the prior year period; a decrease of 14%. Reagents and services revenue continued to increase.
For the first quarter of 2024, reported gross margin was 46% while non-GAAP adjusted gross margin was 57% when excluding the write off from discontinued legacy instruments. Both GAAP and non-GAAP adjusted gross margin were 57% for the first quarter of 2023.
For the first quarter of 2024, operating expenses were $30.0 million and non-GAAP operating expenses were $25.6 million when excluding an impairment charge for facility consolidation and restructuring associated with a reduction in force in January. Both GAAP and non-GAAP operating expenses were $29.7 million for the first quarter of 2023.
For the first quarter of 2024, loss from operations was $21.6 million and non-GAAP loss from operations was $15.2 million, excluding the items noted above. Both GAAP and non-GAAP loss from operations were $17.4 million for the first quarter of 2023.
Ended the quarter with an instrument installed base of 1,213 (354 PhenoCyclers, 859 PhenoImagers), a year-over-year increase of 22% compared to an installed base of 992 in the prior year period (273 PhenoCyclers, 719 PhenoImagers).
1,307 total publications citing Akoya’s technology as of March 31, 2024, compared to 860 total publications in the prior year period: an increase of 52%.
$61.6 million of cash, cash equivalents and marketable securities as of March 31, 2024.
2024 Financial Outlook
Akoya is updating its revenue outlook for the full year 2024 while maintaining its commitment to achieving operating cash flow breakeven by year end. The Company now expects full year 2024 revenue to be in the range of $104.0-$112.0 million.
Webcast and Conference Call Details
Akoya will host a conference call today, May 13, 2024, at 5:00 p.m. Eastern Time to discuss its first quarter 2024 financial results. Investors interested in listening to the conference call are required to register online. A live webcast of the conference call will be available on the “Investors” section of the Company's website at https://investors.akoyabio.com/. The webcast will be archived on the website following the completion of the call for three months.
Non-GAAP Financial Measures
In addition to reporting financial measures in accordance with generally accepted accounting principles (“GAAP”), Akoya is including in this press release “non-GAAP adjusted gross profit,” “non-GAAP adjusted gross margin,” “non-GAAP operating expense,” and “non-GAAP loss from operations,” all of which are non-GAAP financial measures. Akoya defines non-GAAP adjusted gross profit as gross profit margin adjusted for certain excess and obsolete inventory charges. Non-GAAP adjusted gross margin is defined as non-GAAP adjusted gross profit divided by total revenue. Akoya defines non-GAAP operating expense as operating expense adjusted for impairment and restructuring charges. Akoya defines non-GAAP loss from operations as loss from operations adjusted for certain excess and obsolete inventory charges, impairment, and restructuring charges.
Akoya includes these non-GAAP financial measures because it believes they allow investors to understand and evaluate the Company’s core operating performance and trends. In particular, the exclusion of certain items in calculating non-GAAP adjusted gross profit, non-GAAP adjusted gross margin, non-GAAP operating expense, and non-GAAP loss from operations can provide useful measures for period-to-period comparisons of the Company’s core business. These non-GAAP financial measures have limitations as analytical tools, including the fact that such non-GAAP financial measures may not be comparable to similarly titled measures presented by other companies because other companies may calculate non-GAAP adjusted gross profit, non-GAAP adjusted gross margin, non-GAAP operating expense, and non-GAAP loss from operations differently than Akoya does. For more information regarding these non-GAAP financial measures, see the tables included at the end of this press release.
Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our expectations for full year 2024 revenue, our growth prospects, our ability to achieve operating cash flow breakeven, projected timing for achieving operating cash flow breakeven, our expectations regarding our ability to market, sell and meet demand for our products and services, our expectations regarding our current and potential partnerships and collaborations, and other statements regarding our business strategies, use of capital, results of operations, financial and operational performance and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit www.akoyabio.com.
Investor Contact:
Priyam Shah
Media Contact:
Christine Quern
Condensed Consolidated Balance Sheets (unaudited)
(in thousands) March 31, 2024 December 31, 2023Assets Current assets Cash and cash equivalents $ 13,039 $ 83,125 Marketable securities 48,536 — Accounts receivable, net 13,473 16,994 Inventories, net 22,988 17,877 Prepaid expenses and other current assets 3,793 3,794 Total current assets 101,829 121,790 Property and equipment, net 8,964 10,729 Demo inventory, net 726 893 Intangible assets, net 16,699 17,412 Goodwill 18,262 18,262 Operating lease right of use assets, net 5,568 8,365 Financing lease right of use assets, net 1,348 1,562 Other non-current assets 1,354 1,356 Total assets $ 154,750 $ 180,369 Liabilities and Stockholders’ Equity Current liabilities Accounts payable, accrued expenses and other current liabilities $ 23,209 $ 25,209 Current portion of operating lease liabilities 2,654 2,681 Current portion of financing lease liabilities 718 767 Deferred revenue 6,612 6,688 Total current liabilities 33,193 35,345 Deferred revenue, net of current portion 2,928 3,193 Long-term debt, net 75,469 75,254 Contingent consideration liability, net of current portion 4,015 5,765 Operating lease liabilities, net of current portion 5,713 6,238 Financing lease liabilities, net of current portion 634 766 Other long-term liabilities 75 38 Total liabilities 122,027 126,599 Total stockholders' equity 32,723 53,770 Total liabilities and stockholders' equity $ 154,750 $ 180,369
Consolidated Statements of Operations (unaudited)
(in thousands, except share and per share amounts) Three months ended March 31, March 31, 2024 2023 Revenue: Product revenue $ 12,140 $ 15,524 Service and other revenue 6,210 5,886 Total revenue 18,350 21,410 Cost of goods sold: Cost of product revenue 6,723 5,751 Cost of service and other revenue 3,248 3,366 Total cost of goods sold 9,971 9,117 Gross profit 8,379 12,293 Operating expenses: Selling, general and administrative 19,863 23,124 Research and development 5,554 6,378 Change in fair value of contingent consideration 179 227 Impairment 2,971 — Restructuring 1,397 — Total operating expenses 29,964 29,729 Loss from operations (21,585) (17,436)Other income (expense): Interest expense (2,612) (2,054)Interest income 937 765 Other expense, net (161) (48)Loss before provision for income taxes (23,421) (18,773)Provision for income taxes (63) (29)Net loss $ (23,484) $ (18,802)Net loss per share attributable to common stockholders, basic and diluted $ (0.48) $ (0.49)Weighted-average shares outstanding, basic and diluted 49,188,170 38,326,024
Gross Profit to Non-GAAP Adjusted Gross Profit Reconciliation and Calculation of Gross Margin and Non-GAAP Adjusted Gross Margin (unaudited)
(in thousands) Three months ended March 31, March 31, 2024 2023 Total revenue $ 18,350 $ 21,410 Gross profit 8,379 12,293 Provision for excess and obsolete inventories - product discontinuation and lease exit inventory charges 2,045 — Non-GAAP adjusted gross profit $ 10,424 $ 12,293 Gross margin 46% 57% Non-GAAP adjusted gross margin 57% 57%
Operating Expense to Non-GAAP Operating Expense Reconciliation (unaudited)
(in thousands) Three months ended March 31, March 31, 2024 2023Operating expenses $ 29,964 $ 29,729 Impairment (2,971) — Restructuring (1,397) — Non-GAAP operating expenses $ 25,596 $ 29,729
Loss From Operations to Non-GAAP Loss From Operations Reconciliation (unaudited)
(in thousands) Three months ended March 31, March 31, 2024 2023 Loss from operations $ (21,585) $ (17,436)Provision for excess and obsolete inventories - product discontinuation and lease exit inventory charges 2,045 — Impairment 2,971 — Restructuring 1,397 — Non-GAAP loss from operations $ (15,172) $ (17,436)

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.